Cargando…

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

INTRODUCTION: The molecular biology involving neoadjuvant chemotherapy (NAC) response is poorly understood. To elucidate the impact of NAC on the breast cancer transcriptome and its association with clinical outcome, we analyzed gene expression data derived from serial tumor samples of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magbanua, Mark Jesus M., Wolf, Denise M., Yau, Christina, Davis, Sarah E., Crothers, Julia, Au, Alfred, Haqq, Christopher M., Livasy, Chad, Rugo, Hope S., Esserman, Laura, Park, John W., van ’t Veer, Laura J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479083/ https://www.ncbi.nlm.nih.gov/pubmed/26021444 http://dx.doi.org/10.1186/s13058-015-0582-3

Ejemplares similares

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Esserman, Laura J., et al.
Publicado: (2011)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer
por: Magbanua, Mark Jesus M., et al.
Publicado: (2018)

The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context
por: Campbell, Michael J., et al.
Publicado: (2013)

Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis
por: Rugo, Hope S., et al.
Publicado: (2017)

Androgen receptor gene expression in primary breast cancer
por: Vidula, Neelima, et al.
Publicado: (2019)

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
por: Parker, Barbara A., et al.
Publicado: (2023)

A comparison of RNA amplification techniques at sub-nanogram input concentration
por: Lang, Julie E, et al.
Publicado: (2009)

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
por: Wolf, Denise M., et al.
Publicado: (2020)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
por: Wolf, Denise M., et al.
Publicado: (2017)

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
por: Lo, Wei-Ching, et al.
Publicado: (2016)

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
por: Piawah, Sorbarikor, et al.
Publicado: (2019)

Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy
por: Sugimachi, Keishi, et al.
Publicado: (2018)

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
por: Li, Wen, et al.
Publicado: (2020)

Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis
por: Belkora, Jeffrey K, et al.
Publicado: (2009)

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2020)

Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
por: Vidula, Neelima, et al.
Publicado: (2021)

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
por: Clark, Amy S, et al.
Publicado: (2014)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Publisher Correction: Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2021)

Serial CT changes in different components of lung cancer associated with cystic airspace in patients treated with neoadjuvant chemotherapy
por: Dou, Peipei, et al.
Publicado: (2021)

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity
por: Wolf, Denise M., et al.
Publicado: (2014)

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
por: O'Grady, Nicholas, et al.
Publicado: (2021)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?
por: Chen, Qichen, et al.
Publicado: (2021)

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
por: Yu, Katharine, et al.
Publicado: (2023)

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
por: Li, Wen, et al.
Publicado: (2016)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
por: Palli, Swetha Rao, et al.
Publicado: (2015)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
por: Stejskal, Pavel, et al.
Publicado: (2023)

Accuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients
por: Ye, Bei-Bei, et al.
Publicado: (2016)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response
por: Stevens, William, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3qo3t5ugijg38tkeelnpg4n28u